_________________
June 14, 2022 | The acquisition was initiated when ValGenesis leadership saw the strategic product synergy for customers requiring a complete and more integrated platform across the validation lifecycle focusing on Pharma 4.0.
This is the largest consumer goods company based in the U.K. to implement ValGenesis VLMS. The system will drive all the company’s validation programs, including computer system validation (CSV) and equipment qualification.
Cloud-based ValGenesis e-Logbook is Part 11/Annex 11 compliant, built for security-sensitive facilities with restricted network access, and scalable to thousands of users across multiple global sites to enforce consistency and data integrity in all logbook processes.
By combining Zenovative’s expertise with ValGenesis’ validation lifecycle management software, pharmaceutical companies can implement their digitization plans in accordance with the standards of Industry 4.0.
Cloud-based ValGenesis e-Logbook is Part 11/Annex 11 compliant, built for security-sensitive facilities, and can scale to thousands of users across multiple global sites.
ValGenesis’ proven enterprise validation lifecycle management platform currently supports more than 300 sites and 35,000 GxP systems and is used by 30 of the world’s top 50 life sciences companies.
As part of the partnership, ZeeDimension offers the implementation and management of next generation digital validation tools developed by ValGenesis, further strengthening risk and compliance processes. Through ValGenesis, ZeeDimension will serve a wider network of pharmaceutical companies across the globe.
ValGenesis partners with Modis to bring best-in-class digital validation solutions to its clients.
The company, which markets its drugs in over 100 countries, applied sophisticated evaluation criteria that matched vendor capabilities with their demanding business needs. At the end of the process, ValGenesis VLMS was the clear winner.
ValGenesis’ latest customer in Italy develops pharmacological solutions for cardiovascular diseases, oncology, and anti-infectives.